The Lancet Rheumatology
Издатель: Elsevier · ISSN 2665-9913 · 44 статей
- Low TRIM21 signal in Sjögren's: biomarker or analytical interference?
- Low TRIM21 signal in Sjögren's: biomarker or analytical interference? – Authors' reply
- Research in Brief
- Predicting prevalence and severity of cytokine release syndrome after CAR T-cell therapy in patients with autoimmune disease: a retrospective cohort study
- Minimal residual disease flow cytometry of peripheral blood B-cell subsets in patients with idiopathic inflammatory myopathies following rituximab therapy: a single-centre, retrospective cohort study
- Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial
- Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial
- CAR T cells for autoimmune diseases: 2026 update of the EBMT–ISCT–JACIE practice harmonisation and consensus recommendations
- Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies
- A diagnostic enigma: when arteries and muscles collide
- Effect of ethnicity on response to treatment escalation in patients with systemic lupus erythematosus from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a longitudinal cohort study
- The IgG4ward! Foundation guidelines on the treatment of IgG4-related disease
- Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- Harmonising difficult-to-manage and complex-to-manage psoriatic arthritis: from divergent prevalence estimates to reproducible, mechanism-aware phenotypes